Press Release Medicinova Announces New Data And Results Of A Phase 2 Clinical Trial Of Mn 166 Ibudilast In Glioblastoma Presented At The 28th Annual Meeting Of The Society For Neuro Oncology
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Press Release Medicinova Announces New Data And Results Of A Phase 2 Clinical Trial Of Mn 166 Ibudilast In Glioblastoma Presented At The 28th Annual Meeting Of The Society For Neuro Oncology is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange ... Read More
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus